Company

Our mission is

to contribute to well-being of humanity by treating chronic immune diseases through peptide drugs we discover and develop.

Thank you for visiting our website.

KINE SCIENCES is a company that develops ultra-small peptide innovative medicines based on functional immunomics.

We discovered the function of a novel cytokine ERDR1 for the first time in the world and since we have been developing drug candidates of ultra-small peptide with private and public funding including the one from Korea Drug Development Fund for consecutive four years.

The diseases we aim to treat are chronic immune diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease, and many rare immune diseases.

Though we live in an era when we see more research on life sciences and more drugs on the market than any other era of human history, we humans have yet to find cures for these chronic immune diseases by seeing occurrence of resistance or relapse which make lifelong treatment of expensive medicines inevitable for patients.

These diseases put a great burden not only on patients themselves but their families and the society as a whole.

KINE SCIENCES is committed to treating chronic immune diseases, making lives of patients and their families better, and ultimately improving well-being of humanity by developing safer, more economical and more convenient medicines of ultra small peptides.

Please give us encouragement and support for our daunting journey.

Founder

  • CTO Dae Ho Cho

  • Ph.D., Chicago Medical School; B.S., SUNY

    Professor of Convergence Research Institute, Korea University

    Head of Nano Bio Material Research Center, Korea University

    Professor of Department of Life Sciences, Sookmyung Women's University

Executives

CEO
Hee Kyung Kim

MBA, Sogang University; B.S. Pharmacy, Seoul National University

SVP, Clinical Science Division & RA, Samsung Bioepis

VP, Strategic Business Development, Samsung Electronics

Head of Market Access Division & Compliance, Novartis Korea

CFO
Seung Bo Moon

B.A. Business Administration, Korea University

CFO and COO of Hanel

CFO of Meere Company

CPA of Samil PwC

COO
Byoung Jin Seo

MBA, Korea University

Vice President, Strategic Planning & BD, NKMAX

General Manager, M&A Team, Samsung Fire & Marine

Project Manger, A.T Kearney/Deloitte

Analyst, Accenture

Head of Research
Center
Jeong Min Park

M.S. Virolgy & Immunolgy, Ulsan University

Chief Researcher, Central Research Institutes, IL-YANG Pharmaceuticals

Team Leader, SIS Immunology Research Center, Sookmyung Women's University

Head of Research
Planning
Sung Young Park

Ph.D., Cell Biology, Sookmyung Women's University

Senior Researcher, Sookmyung Women's University

Senior Researcher, SIS Immunology Research Center, Sookmyung Women's University

Research Professor, Sookmyung Women’s University

Head of Project
/Process Management
A Yeon Cho

Ph.D., College of Medicine, Seoul National University; B.S. Biological Sciences, KAIST

Chief Researcher, Strategic Business Development Lead, CHABiotech

Principal Engineer, Corporate Management and Business Development, Samsung Bioepis

Senior Engineer, Samsung Advanced Institute of Technology, Samsung Electronics

2022

  • 03
    CEOs of Hee Kyung Kim & Dae Ho Cho inaugurated
    01
    KINE-101B GLP study initiated

2021

  • 12
    Move the head office to PNM Tower
    09
    KINE-101A Phase 1 IND approved by US FDA
    05
    Substance patents regarding KINE-101, KINE-201 and KINE-301 registered in US

2020

  • 07
    Project awarded by Korea Patent Strategy Development Institute

2019

  • 03
    Change of corporate name to KINE SCIENCES Co.,Ltd.
    03
    R&D Center of KINE SCIENCES established
    07
    KINE-101A GLP study initiated
    08
    Corporate R&D Center certification acquisition

2018

  • 10
    Established joint research institute with Korea University
    12
    Certified by Korea Government as a Venture Company

2017

  • 12
    Patents regarding KINE-101, KINE-201 and KINE-301 filed in major foreign conturies

2016

  • 08
    Company founded(Bio Pep Co., Ltd.)
    12
    Selected as a new drug development project by the Ministry of New Drug Development Project
Mission
Contributing to better lives of mankind
by developing innovative therapies
Vision 2025
Growing as a unicorn company
carrying out more than five global clinical trials with new molecules

Core Value

  • CHALLENGE
    Pursuing the best through change and innovation
  • FLEXIBILITY
    Being flexible and adaptable to ever-changing environment
  • JUSTNESS
    Sticking to the principle and being honest
  • COMMITMENT
    Being committed to common goal and vision
  • COLLABORATION
    Moving forward hand in hand
Continuous InnovationRaises Hope for Humanity.